Mechanisms of Sublingual Immunotherapy

References

• Durham S R, Walker S M, Varga E M, Jacobson M R, O'Brien F, Noble W, Till S J, Hamid Q A, Nouri-Aria K T. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999; 341: 468–475
   PubMed Web of Science ®Google Scholar
• Golden D B, Kwiterovich K A, Kagey-Sobotka A, Valentine M D, Lichtenstein L M. Discontinuing venom immunotherapy: outcome after five years. J Allergy Clin Immunol 1996; 97: 579–587
   PubMed Web of Science ®Google Scholar
• Pajno G B, Barberio G, De Luca F, Morabito L, Parmiani S. Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin Exp Allergy 2001; 31: 1392–1397
   PubMed Web of Science ®Google Scholar
• Möller C, Dreborg S, Ferdousi H A, Halken S, Høst A, Jacobsen L, Koivikko A, Koller D Y, Niggemann B, Norberg L A, Urbanek R, Valovirta E, Wahn U. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 2002; 109: 251–256
   PubMed Web of Science ®Google Scholar
• Jacobsen L, Niggemann B, Dreborg S, Ferdousi H A, Halken S, Høst A, Koivikko A, Norberg L A, Valovirta E, Wahn U, Möller C, The PAT investigator group. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy 2007; 62: 943–948
   PubMed Web of Science ®Google Scholar
• Wilson D R, Torres Lima M, Durham S R. Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy 2005; 60: 4–12
   PubMed Web of Science ®Google Scholar
• Calderon M A, Alves B, Jacobson M, Hurwitz B, Sheikh A, Durham S. Cochrane Database Syst Rev 2007, (1):CD001936
   PubMed Web of Science ®Google Scholar
• Durham S R, Yang W H, Pederson M R, Johansen N, Rak S. Sublingual immunotherapy with once-daily grass allergen tablets: A randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006; 117: 802–809
   PubMed Web of Science ®Google Scholar
• Didier A, Malling H J, Worm M, Horak F, Jäger S, Montagut A, André C, de Beaumont O, Melac M. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol 2007; 120: 1338–1345
   PubMed Web of Science ®Google Scholar
• Dahl R, Kapp A, Colombo G, de Monchy J GR, Rak S, Emminger W, Riis B, Grønager P M, Durham S R. Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years. J Allergy Clin Immunol 2008; 121: 512–518
   PubMed Web of Science ®Google Scholar
• Nouri-Aria K T, Wachholz P A, Francis J N, Jacobson M R, Walker S M, Wilcock L K, Staple S Q, Aalberse R C, Till S J, Durham S R. Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J Immunol 2004; 172: 3252–3259
   PubMed Web of Science ®Google Scholar
• Mothes N, Heinzkill M, Drachenberg K J, Sperr W R, Krauth M T, Majlesi Y, Semper H, Valent P, Niederberger V, Kraft D, Valenta R. Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies. Clin Exp Allergy 2003; 33: 1198–1208
   PubMed Web of Science ®Google Scholar
• Jutel M, Akdis M, Budak F, Aebischer-Casaulta C, Wrzyszcz M, Blaser K, Akdis C A. IL-10 and TGF-β cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur J Immunol 2003; 33: 1205–1214
   PubMed Web of Science ®Google Scholar
• Pilette C, Nouri-Aria K T, Jacobson M R, Wilcock L K, Detry B, Walker S M, Francis J N, Durham S R. Grass pollen immunotherapy induces an allergen-specific IgA2 antibody response associated with mucosal TGF-β expression. J Immunol 2007; 178: 4658–4666
   PubMed Web of Science ®Google Scholar
• Wachholz P A, Durham S R. Induction of ‘blocking’ IgG antibodies during immunotherapy. Clin Exp Allergy 2003; 33: 1171–1174
   PubMed Web of Science ®Google Scholar
• Shamji M H, Wilcock L K, Wachholz P A, Dearman R J, Kimber I, Wurtzen P A, Larché M, Durham S R, Francis J N. The IgE-facilitated allergen binding (FAB) assay: validation of a novel flow-cytometric based method for the detection of inhibitory antibody responses. J Immunol Meth 2006; 317: 71–79
   PubMed Web of Science ®Google Scholar
• Daëron M, Malbec O, Latour S, Arock M, Fridman W H. Regulation of high-affinity IgE receptor-mediated mast cell activation by low-affinity IgG receptors. J Clin Invest 1995; 95: 577–585
   PubMed Web of Science ®Google Scholar
• Malbec O, Fong D C, Turner M, Tybulewicz V L, Cambier J C, Fridman W H, Daëron M. Fc epsilon receptor I-associated lyn-dependent phosphorylation of Fc gamma receptor IIB during negative regulation of mast cell activation. J Immunol 1998; 160: 1647–1658
   PubMed Web of Science ®Google Scholar
• Zhu D, Kepley C L, Zhang M, Zhang K, Saxon A. A novel human immunoglobulin Fc-gamma- Fc-epsilon bifunctional fusion protein inhibits Fc-epsilon RI-mediated degranulation. Nat Med, 8: 518–521
   PubMed Web of Science ®Google Scholar
• Tam S W, Demissie S, Thomas D, Daëron M. A bispecific antibody against human IgE and human Fc- gamma RII that inhibits antigen-induced histamine release by human mast cells and basophils. Allergy 2004; 59: 772–780
   PubMed Web of Science ®Google Scholar
• Wilson D R, Irani A M, Walker S M, Jacobson M R, Mackay I S, Schwartz L B, Durham S R. Grass pollen immunotherapy inhibits seasonal increases in basophils and eosinophils in the nasal epithelium. Clin Exp Allergy 2001; 31: 1705–1713
   PubMed Web of Science ®Google Scholar
• Durham S R, Ying S, Varney V A, Jacobson M R, Sudderick R M, Mackay I S, Kay A B, Hamid Q A. Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-gamma. J Allergy Clin Immunol 1996; 97: 1356–1365
   PubMed Web of Science ®Google Scholar
• Ling E M, Smith T, Nguyen X D, Pridgeon C, Dallman M, Arbery J, Carr V A, Robinson D S. Relation of CD4+CD25+ regulatory T-cell suppression of allergen-driven T-cell activation to atopic status and expression of allergic disease. Lancet 2004; 363(9409)608–615
   PubMed Web of Science ®Google Scholar
• Robinson D S, Larché M, Durham S R. Tregs and allergic disease. J Clin Invest 2004; 114: 1389–1397
   PubMed Web of Science ®Google Scholar
• Francis J N, Till S J, Durham S R. Induction of IL-10+CD4+CD25+ T cells by grass pollen immunotherapy. J Allergy Clin Immunol 2003; 111: 1255–1261
   PubMed Web of Science ®Google Scholar
• Ebner C, Siemann U, Bohle B, Willheim M, Wiedermann U, Schenk S, Klotz F, Ebner H, Kraft D, Scheiner O. Immunological changes during specific immunotherapy of grass pollen allergy: reduced lymphoproliferative responses to allergen and shift from TH2 to TH1 in T-cell clones specific for Phl p 1, a major grass pollen allergen. Clin Exp Allergy 1997; 27: 1007–1015
   PubMed Web of Science ®Google Scholar
• Till S, Walker S, Dickason R, Huston D, O'Brien F, Lamb J, Kay A B, Corrigan C, Durham S. IL-5 production by allergen-stimulated T cells following grass pollen immunotherapy for seasonal allergic rhinitis. Clin Exp Immunol 1997; 110: 114–121
   PubMed Web of Science ®Google Scholar
• Wachholz P A, Nouri-Aria K T, Wilson D R, Walker S M, Verhoef A, Till S J, Durham S R. Grass pollen immunotherapy for hayfever is associated with increases in local nasal but not peripheral Th1:Th2 cytokine ratios. Immunology 2002; 105: 56–62
   PubMed Web of Science ®Google Scholar
• Klimek L, Dormann D, Jarman E R, Cromwell O, Riechelmann H, Reske-Kunz A B. Short-term preseasonal birch pollen allergoid immunotherapy influences symptoms, specific nasal provocation and cytokine levels in nasal secretions, but not peripheral T-cell responses, in patients with allergic rhinitis. Clin Exp Allergy 1999; 29: 1326–1335
   PubMed Web of Science ®Google Scholar
• Radulovic S, Jacobson M R, Durham S R, Nouri-Aria K T. Grass pollen immunotherapy induces Foxp3-expressing CD4+ CD25+ cells in the nasal mucosa. J Allergy Clin Immunol 2008; 121: 1467–1472
   PubMed Web of Science ®Google Scholar
• Akdis C A, Joss A, Akdis M, Faith A, Blaser K. A molecular basis for T cell suppression by IL-10: CD28-associated IL-10 receptor inhibits CD28 tyrosine phosphorylation and phosphatidylinositol 3-kinase binding. FASEB J 2000; 14: 1666–1668
   PubMed Web of Science ®Google Scholar
• Jeannin P, Lecoanet S, Delneste Y, Gauchat J F, Bonnefoy J Y. IgE versus IgG4 production can be differentially regulated by IL-10. J Immunol 1998; 160: 3555–3561
   PubMed Web of Science ®Google Scholar
• Bagnasco M, Mariani G, Passalacqua G, Motta C, Bartolomei M, Falagiani P, Mistrello G, Canonica G W. Absorption and distribution kinetics of the major Parietaria judaica allergen (Par j 1) administered by noninjectable routes in healthy human beings. J Allergy Clin Immunol 1997; 100: 122–129
   PubMed Web of Science ®Google Scholar
• Bagnasco M, Passalacqua G, Villa G, Augeri C, Flamigni G, Borini E, Falagiani P, Mistrello G, Canonica G W, Mariani G. Pharmacokinetics of an allergen and a monomeric allergoid for oromucosal immunotherapy in allergic volunteers. Clin Exp Allergy 2001; 31: 54–60
   PubMed Web of Science ®Google Scholar
• Razafindratsita A, Saint-Lu N, Mascarell L, Berjont N, Bardon T, Betbeder D, Van Overtvelt L, Moingeon P. Improvement of sublingual immunotherapy efficacy with a mucoadhesive allergen formulation. J Allergy Clin Immunol 2007; 120: 278–285
   PubMed Web of Science ®Google Scholar
• Allam J P, Novak N, Fuchs C, Asen S, Bergé S, Appel T, Geiger E, Kochan J P, Bieber T. Characterization of dendritic cells from human oral mucosa: a new Langerhans' cell type with high constitutive Fc-epsilon RI expression. J Allergy Clin Immunol 2003; 112: 141–148
   PubMed Web of Science ®Google Scholar
• Noirey N, Rougier N, André C, Schmitt D, Vincent C. Langerhans-like dendritic cells generated from cord blood progenitors internalize pollen allergens by macropinocytosis, and part of the molecules are processed and can activate autologous naive T lymphocytes. J Allergy Clin Immunol 2000; 105: 1194–1201, (6 pt 1)
   PubMed Web of Science ®Google Scholar
• Allam J P, Stojanovski G, Friedrichs N, Peng W, Bieber T, Wenzel J, Novak N. Distribution of Langerhans cells and mast cells within the human oral mucosa: new application sites of allergens in sublingual immunotherapy?. Allergy 2008; 63: 720–727
   PubMed Web of Science ®Google Scholar
• Zemann B, Schwaerzler C, Griot-Wenk M, Nefzger M, Mayer P, Schneider H, de Weck A, Carballido J M, Liehl E. Oral administration of specific antigens to allergy-prone infant dogs induces IL-10 and TGF- beta expression and prevents allergy in adult life. J Allergy Clin Immunol 2003; 111: 1069–1075
   PubMed Web of Science ®Google Scholar
• Akbari O, DeKruyff R H, Umetsu D T. Pulmonary dendritic cells producing IL-10 mediate tolerance induced by respiratory exposure to antigen. Nat Immunol 2001; 2: 725–731
   PubMed Web of Science ®Google Scholar
• Wakkach A, Fournier N, Brun V, Breittmayer J P, Cottrez F, Groux H. Characterization of dendritic cells that induce tolerance and T regulatory 1 cell differentiation in vivo. Immunity 2003; 18: 605–617
   PubMed Web of Science ®Google Scholar
• Van Wilsem E J, Van Hoogstraten I M, Brevé J, Scheper R J, Kraal G. Dendritic cells of the oral mucosa and the induction of oral tolerance. A local affair. Immunology 1994; 83: 128–132
   PubMed Web of Science ®Google Scholar
• Novak N, Bieber T, Katoh N. Engagement of Fc epsilon RI on human monocytes induces the production of IL-10 and prevents their differentiation in dendritic cells. J Immunol 2001; 167: 797–804
   PubMed Web of Science ®Google Scholar
• von Bubnoff D, Matz H, Frahnert C, Rao M L, Hanau D, de la Salle H, Bieber T. Fc-epsilonRI induces the tryptophan degradation pathway involved in regulating T cell responses. J Immunol 2002; 169: 1810–1816
   PubMed Web of Science ®Google Scholar
• Allam J P, Peng W M, Appel T, Wenghoefer M, Niederhagen B, Bieber T, Bergé S, Novak N. Toll-like receptor 4 ligation enforces tolerogenic properties of oral mucosal Langerhans cells. J Allergy Clin Immunol 2008; 121: 368–374
   PubMed Web of Science ®Google Scholar
• Van Overtvelt L, Lombardi V, Razafindratsita A, Saint-Lu N, Horiot S, Moussu H, Mascarell L, Moingeon P. IL-10-inducing adjuvants enhance sublingual immunotherapy efficacy in a murine asthma model. Int Arch Allergy Immunol 2008; 145: 152–162
   PubMed Web of Science ®Google Scholar
• Brimnes J, Kildsgaard J, Jacobi H, Lund K. Sublingual immunotherapy reduces allergic symptoms in a mouse model of rhinitis. Clin Exp Allergy 2007; 37: 488–497
   PubMed Web of Science ®Google Scholar
• Petersen A B, Gudmann P, Milvang-Grønager P, Mørkeberg R, Bøgestrand S, Linneberg A, Johansen N. Performance evaluation of a specific IgE assay developed for the ADVIA centaur immunoassay system. Clin Biochem 2004; 37: 882–892
   PubMed Web of Science ®Google Scholar
• Radulovic S, Calderon M, Wilson S, Durham S. Sublingual immunotherapy for allergic rhinitis: an updated Cochrane systemic review and meta-analysis. Allergy 2007; 62(suppl 83)263
   Google Scholar
• Marcucci F, Sensi L, Di Cara G, Incorvaia C, Frati F. Dose dependence of immunological response to sublingual immunotherapy. Allergy 2005; 60: 952–956
   PubMed Web of Science ®Google Scholar
• Lima M T, Wilson D, Pitkin L, Roberts A, Nouri-Aria K, Jacobson M, Walker S, Durham S. Grass pollen sublingual immunotherapy for seasonal rhinoconjunctivitis: a randomized controlled trial. Clin Exp Allergy 2002; 32: 507–514
   PubMed Web of Science ®Google Scholar
• Rossi R E, Monasterolo G, Coco G, Silvestro L, Operti D. Evaluation of serum IgG4 antibodies specific to grass pollen allergen components in the follow up of allergic patients undergoing subcutaneous and sublingual immunotherapy. Vaccine 2007; 25: 957–964
   PubMed Web of Science ®Google Scholar
• André C, Perrin-Fayolle M, Grosclaude M, Couturier P, Basset D, Cornillon J, Piperno D, Girodet B, Sanchez R, Vallon C, Bellier P, Nasr M. A double-blind placebo-controlled evaluation of sublingual immunotherapy with a standardized ragweed extract in patients with seasonal rhinitis. Evidence for a dose-response relationship. Int Arch Allergy Immunol 2003; 131: 111–118
   PubMed Web of Science ®Google Scholar
• Bousquet J, Scheinmann P, Guinnepain M T, Perrin-Fayolle M, Sauvaget J, Tonnel A B, Pauli G, Caillaud D, Dubost R, Leynadier F, Vervloet D, Herman D, Galvain S, André C. Sublingual-swallow immunotherapy (SLIT) in patients with asthma due to house-dust mites: a double-blind, placebo-controlled study. Allergy 1999; 54: 249–260
   PubMed Web of Science ®Google Scholar
• Lue K H, Lin Y H, Sun H L, Lu K H, Hsieh J C, Chou M C. Clinical and immunologic effects of sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, randomized, placebo-controlled study. Pediatr Allergy Immunol 2006; 17: 408–415
   PubMed Web of Science ®Google Scholar
• Aberer W, Hawranek T, Reider N, Schuster C, Sturm G, Kränke B. Immunoglobulin E and G antibody profiles to grass pollen allergens during a short course of sublingual immunotherapy. J Investig Allergol Clin Immunol 2007; 17: 131–136
   PubMed Web of Science ®Google Scholar
• Rolinck-Werninghaus C, Kopp M, Liebke C, Lange J, Wahn U, Niggemann B. Lack of detectable alterations in immune responses during sublingual immunotherapy in children seasonal allergic rhinoconjunctivitis to grass pollen. Int Arch Allergy Immunol 2005; 136: 134–141
   PubMed Web of Science ®Google Scholar
• Pajno G B, Morabito L, Barberio G, Parmiani S. Clinical and immunologic effects of long-term sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, placebo-controlled study. Allergy 2000; 55: 842–849
   PubMed Web of Science ®Google Scholar
• Tonnel A B, Scherpereel A, Douay B, Mellin B, Leprince D, Goldstein N, Delecluse P, Andre C. Allergic rhinitis due to house dust mites: evaluation of the efficacy of specific sublingual immunotherapy. Allergy 2004; 59: 491–497
   PubMed Web of Science ®Google Scholar
• Bahceciler N N, Arikan C, Taylor A, Akdis M, Blaser K, Barlan I B, Akdis C A. Impact of sublingual immunotherapy on specific antibody levels in asthmatic children allergic to house dust mites. Int Arch Allergy Immunol 2005; 136: 287–294
   PubMed Web of Science ®Google Scholar
• Dehlink E, Eiwegger T, Gerstmayr M, Kampl E, Bohle B, Chen K W, Vrtala S, Urbanek R, Szépfalusi Z. Absence of systemic immunologic changes during dose build-up phase and early maintenance period in effective specific sublingual immunotherapy in children. Clin Exp Allergy 2006; 36: 32–39
   PubMed Web of Science ®Google Scholar
• Passalacqua G, Albano M, Fregonese L, Riccio A, Pronzato C, Mela G S, Canonica G W. Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinoconjunctivitis. Lancet 1998; 351(9103)629–632
   PubMed Web of Science ®Google Scholar
• Passalacqua G, Albano M, Riccio A, Fregonese L, Puccinelli P, Parmiani S, Canonica G W. Clinical and immunologic effects of a rush sublingual immunotherapy to Parietaria species: A double-blind, placebo-controlled trial. J Allergy Clin Immunol 1999; 104: 964–968
   PubMed Web of Science ®Google Scholar
• Arikan C, Bahceciler N N, Deniz G, Akdis M, Akkoc T, Akdis C A, Barlan I B. Bacillus Calmette-Guérin-induced interleukin-12 did not additionally improve clinical and immunologic parameters in asthmatic children treated with sublingual immunotherapy. Clin Exp Allergy 2004; 34: 398–405
   PubMed Web of Science ®Google Scholar
• Ippoliti F, De Santis W, Volterrani A, Lenti L, Canitano N, Lucarelli S, Frediani T. Immunomodulation during sublingual therapy in allergic children. Pediatr Allergy Immunol 2003; 14: 216–221
   PubMed Web of Science ®Google Scholar
• Marcucci F, Sensi L, Frati F, Senna G E, Canonica G W, Parmiani S, Passalacqua G. Sublingual tryptase and ECP in children treated with grass pollen sublingual immunotherapy (SLIT): safety and immunologic implications. Allergy 2001; 56: 1091–1095
   PubMed Web of Science ®Google Scholar
• Castells M, Schwartz L B. Tryptase levels in nasal-lavage fluid as an indicator of the immediate allergic response. J Allergy Clin Immunol 1988; 82: 348–355, (3 Pt 1)
   PubMed Web of Science ®Google Scholar
• Marcucci F, Sensi L, Incorvaia C, Di Cara G, Moingeon P, Frati F. Oral reactions to sublingual immunotherapy: a bioptic study. Allergy 2007; 62: 1475–1477
   PubMed Web of Science ®Google Scholar
• Bohle B, Kinaciyan T, Gerstmayr M, Radakovics A, Jahn-Schmid B, Ebner C. Sublingual immunotherapy induces IL-10-producing T regulatory cells, allergen-specific T-cell tolerance, and immune deviation. J Allergy Clin Immunol 2007; 120: 707–713
   PubMed Web of Science ®Google Scholar
• Fanta C, Bohle B, Hirt W, Siemann U, Horak F, Kraft D, Ebner H, Ebner C. Systemic immunological changes induced by administration of grass pollen allergens via the oral mucosa during sublingual immunotherapy. Int Arch Allergy Immunol 1999; 120: 218–224
   PubMed Web of Science ®Google Scholar
• Cosmi L, Santarlasci V, Angeli R, Liotta F, Maggi L, Frosali F, Rossi O, Falagiani P, Riva G, Romagnani S, Annunziato F, Maggi E. Sublingual immunotherapy with Dermatophagoides monomeric allergoid down-regulates allergen-specific immunoglobulin E and increases both interferon-gamma- and interleukin-10-production. Clin Exp Allergy 2006; 36: 261–272
   PubMed Web of Science ®Google Scholar
• Ciprandi G, Fenoglio D, Cirillo I, Vizzaccaro A, Ferrera A, Tosca M A, Puppo F. Induction of interleukin 10 by sublingual immunotherapy for house dust mites: a preliminary report. Ann Allergy Asthma Immunol 2005; 95: 38–44
   PubMed Web of Science ®Google Scholar
• Fenoglio D, Puppo F, Cirillo I, Vizzaccaro A, Ferrera A, Tosca M A, Marseglia G, Ciprandi G. Sublingual specific immunotherapy reduces PBMC proliferations. Eur Ann Allergy Clin Immunol 2005; 37: 147–151
   PubMedGoogle Scholar
• Savolainen J, Jacobsen L, Valovirta E. Sublingual immunotherapy in children modulates allergen-induced in vitro expression of cytokine mRNA in PBMC. Allergy 2006; 61: 1184–1190
   PubMed Web of Science ®Google Scholar
• Savolainen J, Nieminen K, Laaksonen K, Laiho T, Jacobsen L, Lahesmaa R, Terho E O, Valovirta E. Allergen-induced in vitro expression of IL-18, SLAM and GATA-3 mRNA in PBMC during sublingual immunotherapy. Allergy 2007; 62: 949–953
   PubMed Web of Science ®Google Scholar
• Ciprandi G, Cirillo I, Fenoglio D, Marseglia G, Tosca M A. Sublingual immunotherapy induces spirometric improvement associated with IL-10 production: preliminary reports. Int Immunopharmacol 2006; 6: 1370–1373
   PubMed Web of Science ®Google Scholar
• Moingeon P, Batard T, Fadel R, Frati F, Sieber J, Van Overtvelt L. Immune mechanisms of allergen-specific sublingual immunotherapy. Allergy 2006; 61: 151–165
   PubMed Web of Science ®Google Scholar